汇添富国证港股通创新药ETF发起式联接C(021031)财务指标
| |
2025-12-31 |
2025-06-30 |
2024-12-31 |
2024-06-30 |
| 本期已实现收益 |
172,921,573.44 |
22,287,107.37 |
1,404,746.52 |
-156,159.77 |
| 本期利润 |
-315,301,140.59 |
96,426,658.99 |
-286,275.18 |
-1,841,212.73 |
| 加权平均基金份额本期利润 |
-0.32 |
0.42 |
-0.01 |
-0.14 |
| 本期加权平均净值利润率(%) |
-16.58 |
28.27 |
-0.70 |
-14.21 |
| 本期基金份额净值增长率(%) |
54.87 |
53.27 |
9.65 |
-7.63 |
| 期末可供分配利润 |
425,298,031.98 |
72,620,067.58 |
506,952.82 |
-1,049,627.85 |
| 期末可供分配基金份额利润 |
0.20 |
0.08 |
0.01 |
-0.08 |
| 期末基金资产净值 |
3,560,207,044.77 |
1,510,119,838.25 |
93,213,425.46 |
12,715,118.68 |
| 期末基金份额净值 |
1.70 |
1.68 |
1.10 |
0.92 |
| 基金份额累计净值增长率(%) |
69.82 |
68.06 |
9.65 |
-7.63 |
微信公众号
证券之星APP
基本资料
